Immunotherapy in Melanoma | Specialty

Expanded RAS Mutation Testing in mCRC

January 1st 2015

2014 Year in Review

January 1st 2015

FDA Approves Nivolumab for Advanced Melanoma

December 22nd 2014

The FDA has approved the PD-1 inhibitor nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor.

The Evolving Treatment Landscape in Advanced Melanoma

December 18th 2014

Metastatic melanoma is associated with a poor prognosis, but recent breakthroughs in tumor biology and immune regulation have led to the development of agents that could change clinical practice.

Rosenberg's Many Breakthroughs Fueled by Passion and Hard Work

November 21st 2014

Steven Rosenberg always knew that he wanted to become a physician scientist, and he quickly advanced to become the chief of surgery at the National Cancer Institute (NCI) at just 34 years of age.

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014

ADT With GnRH Antagonists in Prostate Cancer

November 21st 2014

Upcoming Advances for GU Cancers

November 21st 2014

Latest News & Insight: November 20, 2014

November 21st 2014

Nivolumab Extends Survival in Phase III Melanoma Study

November 17th 2014

Frontline treatment with nivolumab significantly extended OS and PFS compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.

Pembrolizumab Improves PFS, ORR Versus Chemotherapy in Phase II Melanoma Study

November 16th 2014

The PD-1 inhibitor pembrolizumab significantly improved PFS by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab.

Rindopepimut Leads to Improved PFS in Compassionate Use Study

November 16th 2014

The vaccine rindopepimut appears to help PFS and OS in patients with epidermal growth factor receptor variant III mutation in glioblastoma-a patient group with traditionally poor outcomes.

Adding GM-CSF to Ipilimumab Improves OS, Lowers Toxicity in Advanced Melanoma

November 5th 2014

The addition of the GM-CSF agent sargramostim to the CTLA-4 inhibitor ipilimumab (Yervoy) prolonged overall survival (OS) and lowered toxicity for patients with unresectable stage III or IV melanoma

New Vaccine Formulation Effective in Low-Grade Lymphoma

November 5th 2014

The combination of a FLT3L-primed in situ vaccine, low-dose radiotherapy, and a toll-like receptor 3 (TLR) 3 agonist has been shown to be feasible, safe, and immunologically and clinically effective in a phase I/II study for patients with low-grade lymphoma

New Study Links Socioeconomic Factors and Fashion Trends Over the Past Century to Increased Incidence of Melanoma

October 31st 2014

Researchers analyzed artwork, advertisements and leisure time activities to estimate historic changes in UV exposure

FDA Expands Approval of Lymphoseek to Breast Cancer and Melanoma

October 15th 2014

The FDA has expanded the approval of Lymphoseek (technetium Tc 99m tilmanocept) injection to include lymphatic mapping in solid tumors and sentinel lymph node (SLN) detection for breast cancer and melanoma

Is Breast Cancer Vaccination Coming?

October 1st 2014

Dr. Patrick Borgen Talks About Advances in Breast Cancer

October 1st 2014

Dr. Patrick Borgen Discusses the "Jolie Effect"

October 1st 2014

Dr. Patrick Borgen on the Future of Breast Cancer Treatment

October 1st 2014